NASDAQ: BGLC
BioNexus Gene Lab CorpCIK 0001737523 · SIC 8071 · Health Services
As at December 31, 2025, common stock, no par value; 300,000,000 shares authorized and 2,417,314 shares outstanding, and preferred stock, no par value; 30,000,000 shares authorized and no shares outstanding. As at December 31, 2024, common stock, no par value; 300,000,000 shares authorized and… About this business →
Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.
Sign up freeWant to see a complete report first? Today's free report (JEF 10-Q) is open in full — no account needed.
Summary not yet generated.
Summary not yet generated.
Partner
Trade BGLC commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Latest financial statements
From 10-Q filed Nov 19, 2026 (period ending Sep 30, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.
Condensed Consolidated Statements of Operations and Comprehensive Income (Unaudited)
| Description | Three-month periods ended September 30, 2026 | Three-month periods ended September 30, 2025 | Nine-month periods ended September 30, 2026 | Nine-month periods ended September 30, 2025 |
|---|---|---|---|---|
| REVENUE (Including $nil and $25,649 of revenue from related parties for the three-month period ended September 30, 2026 and 2025, respectively, and $nil and $57,632 of revenue from related parties for the nine-month period ended September 30, 2026 and 2025, respectively) | 47,917 | 2,543,823 | 146,915 | 6,941,151 |
| COST OF REVENUE (Including $nil and $7,233 of cost of revenue from related parties for the three-month period ended September 30, 2026 and 2025, respectively, and $nil and $9,404 of cost of revenue from related parties for the nine-month period ended September 30, 2026 and 2025, respectively) | (43,429) | (2,166,138) | (130,235) | (5,851,951) |
| GROSS PROFIT | 4,488 | 377,685 | 16,680 | 1,089,200 |
| OTHER INCOME | ||||
| Dividend income | - | 4,192 | - | 21,752 |
| Interest income | 16,541 | 20,778 | 54,903 | 74,114 |
| Fair value gain on investments in equity securities | - | - | - | 28,256 |
| Gain on disposal of investments in equity securities | - | 42,376 | - | 42,376 |
| Gain from foreign exchange | 4,402 | - | 10,065 | - |
| Others | 6,239 | 40,414 | 22,779 | 147,231 |
| TOTAL OTHER INCOME | 27,182 | 107,760 | 87,747 | 313,729 |
| OPERATING EXPENSES | ||||
| Sales and marketing | (35,007) | (551,569) | (123,762) | (1,700,691) |
| Research and development | (13,578) | (14,876) | (41,736) | (39,572) |
| General and administrative (Including $nil and $1,065 of rental expenses to related party for the three month period ended September 30, 2026 and 2025, respectively, and $nil and $3,156 of rental expenses to related party for the nine-month period ended September 30, 2026 and 2025, respectively) | (311,387) | (448,791) | (942,942) | (1,364,077) |
| Fair value loss on investments in equity securities | - | - | - | (119,499) |
| Provision for credit losses, net | 75,721 | (175,818) | (76,814) | (121,030) |
| Share-based compensation | (799,998) | - | (799,998) | - |
| TOTAL OPERATING EXPENSES | (1,084,249) | (1,191,054) | (1,985,252) | (3,344,869) |
| LOSS FROM OPERATIONS | (1,052,579) | (705,609) | (1,880,825) | (1,941,940) |
| FINANCE COSTS | (1,801) | (3,382) | (3,581) | (6,550) |
| LOSS BEFORE TAX | (1,054,380) | (708,991) | (1,884,406) | (1,948,490) |
| Tax expense | - | - | - | - |
| NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS | (1,054,380) | (708,991) | (1,884,406) | (1,948,490) |
| Other comprehensive (loss)/income | ||||
| Foreign currency translation (loss)/gain | (2,852) | 3,216 | (9,312) | 442,453 |
| COMPREHENSIVE LOSS | (1,057,232) | (705,775) | (1,893,718) | (1,506,037) |
| Loss per share Basic and diluted | (0.392) | (0.395) | (0.751) | (1.085) |
| Weighted average number of common shares outstanding, Basic and Diluted # | 2,692,209 | 1,796,597 | 2,509,953 | 1,796,597 |
Condensed Consolidated Balance Sheets
| Description | September 30, 2026 (Unaudited) | December 31, 2025 (Audited) |
|---|---|---|
| ASSETS | ||
| CURRENT ASSETS | ||
| Cash and bank balances | 865,804 | 2,383,369 |
| Fixed deposits placed with financial institutions (including $1,139,737 and $1,553,322 of fixed deposits with original maturities more than three months as of September 30, 2026 and December 31, 2025 respectively) | 2,497,798 | 1,656,336 |
| Trade receivables, net of allowance for credit losses of $773,304 and $703,995 as of September 30, 2026 and December 31, 2025 respectively (including $nil and $31,420 of trade receivables from related party as of September 30, 2026 and December 31, 2025 respectively) | 38,142 | 505,885 |
| Other receivables, deposits and prepayments | 89,502 | 81,728 |
| Tax recoverable | 61,105 | 61,384 |
| Inventories | 636,226 | 676,703 |
| Total current assets | 4,188,577 | 5,365,405 |
| NON-CURRENT ASSETS | ||
| Other assets | 833,330 | 83,333 |
| Operating lease right-of-use assets | 131,017 | 177,737 |
| Finance lease right-of-use assets | 69,424 | - |
| Property, plant and equipment, net | 1,511,930 | 1,598,769 |
| Investments in equity securities | 2,026,423 | 2,027,540 |
| Total non-current assets | 4,572,124 | 3,887,379 |
| TOTAL ASSETS | 8,760,701 | 9,252,784 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| CURRENT LIABILITIES | ||
| Trade payables | 12,517 | 2,335 |
| Other payables and accrued liabilities (including $504,330 and $83,333 of other payables to related party as of September 30, 2026 and December 31, 2025 respectively) | 806,519 | 401,611 |
| Operating lease liabilities | 55,506 | 59,147 |
| Finance lease liabilities | 6,862 | - |
| Advance payment from customer | 8,347 | 8,385 |
| Amount owing to directors | 230,277 | 49,479 |
| Total current liabilities | 1,120,028 | 520,957 |
| NON-CURRENT LIABILITIES | ||
| Operating lease liabilities | 75,435 | 116,899 |
| Finance lease liabilities | 44,030 | - |
| Total non-current liabilities | 119,465 | 116,899 |
| TOTAL LIABILITIES | 1,239,493 | 637,856 |
| COMMITMENT AND CONTINGENCIES | - | - |
| STOCKHOLDERS’ EQUITY | ||
| As at September 30, 2026, common stock, no par value; 300,000,000 shares authorized and 2,933,442 shares outstanding, and preferred stock, no par value; 30,000,000 shares authorized and no shares outstanding. As at December 31, 2025, common stock, no par value; 300,000,000 shares authorized and 2,417,314 shares outstanding, and preferred stock, no par value; 30,000,000 shares authorized and no shares outstanding (on a post-reverse stock split basis)*. | 20,974,793 | 20,174,795 |
| Additional paid in capital | (5,011,891) | (5,011,891) |
| Accumulated deficit | (8,311,633) | (6,427,227) |
| Accumulated other comprehensive losses | (130,061) | (120,749) |
| TOTAL STOCKHOLDERS’ EQUITY | 7,521,208 | 8,614,928 |
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | 8,760,701 | 9,252,784 |
Condensed Consolidated Statements of Cash Flows (Unaudited)
| Description | Nine-month periods ended September 30, 2026 | Nine-month periods ended September 30, 2025 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net loss | (1,884,406) | (1,948,490) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Amortization of operating lease ROU assets | 46,669 | 41,666 |
| Amortization of finance lease ROU assets | 5,397 | - |
| Provision for credit losses, net | 76,814 | 121,030 |
| Depreciation of property, plant and equipment | 84,040 | 83,443 |
| Dividend income | - | (21,752) |
| Fair value loss on investments in equity securities | - | 91,243 |
| Gain on disposal of investments in equity securities | - | (27,547) |
| Share-based compensation | 799,998 | - |
| Operating loss before working capital changes | (871,488) | (1,660,407) |
| Changes in operating assets and liabilities: | ||
| Inventories | 40,477 | 381,176 |
| Trade and other receivables | 383,155 | (161,860) |
| Other assets | (749,997) | - |
| Trade and other payables | 415,090 | (1,227,454) |
| Advance payment from customer | (38) | (84,615) |
| Operating lease liabilities | (45,105) | (26,811) |
| Tax recoverable | 279 | (19,473) |
| Net cash used in operating activities | (827,627) | (2,799,444) |
| Cash flows from investing activities: | ||
| Acquisition of investments in equity securities | - | (9,064) |
| Dividend income | - | 21,752 |
| Change in fixed deposits placed with original maturities more than three months | 413,584 | (47,099) |
| Payment for acquisition of right-of-use assets | (21,008) | - |
| Purchase of plant and equipment | (3,103) | (35,994) |
| Proceeds from disposal of investments in equity securities | - | 1,020,873 |
| Net cash generated from investing activities | 389,473 | 950,468 |
| Cash flows from financing activities: | ||
| Advances from Directors | 180,798 | 32,802 |
| Repayment of finance lease liabilities | (3,483) | - |
| Cash paid for fractional shares in reverse stock split | - | (505) |
| Net cash generated from financing activities | 177,315 | 32,297 |
| Foreign currency translation adjustment | (1,679) | 286,805 |
| NET CHANGE IN CASH AND CASH EQUIVALENTS | (262,518) | (1,529,874) |
| CASH AND CASH EQUIVALENTS, BEGINNING OF FINANCIAL PERIOD | 2,486,383 | 2,886,966 |
| CASH AND CASH EQUIVALENTS, END OF FINANCIAL PERIOD | 2,223,865 | 1,357,092 |
| CASH AND CASH EQUIVALENTS INFORMATION: | ||
| Fixed deposits placed with financial institutions with original maturities of three-months or less | 1,358,061 | 203,971 |
| Cash and bank balances | 865,804 | 1,153,121 |
| Cash and cash equivalents, end of financial period | 2,223,865 | 1,357,092 |
| Supplementary cash flow information: | ||
| Interest paid | (11,192) | (16,270) |
| Income tax paid | - | (14,669) |
Amounts as printed on the EDGAR/iXBRL face. Labels, columns, and figures are the filing face, not a GAAP stencil. Interactive statements & notes on EDGAR ↗
About BioNexus Gene Lab Corp
Source: Item 1 (Business) from the 10-K filed April 14, 2026. Description as filed by the company with the SEC.
ITEM 1. FINANCIAL STATEMENTS (CONT’D)
CONSOLIDATED BALANCE SHEETS
AS OF DECEMBER 31, 2025 AND 2024
(Currency expressed in United States Dollars (“US$”))
(Audited)
As of
December 31,
December 31,
Note
2025
2024
COMMITMENT AND CONTINGENCIES
-
-
STOCKHOLDERS’ EQUITY
As at December 31, 2025, common stock, no par value; 300,000,000 shares authorized and 2,417,314 shares outstanding, and preferred stock, no par value; 30,000,000 shares authorized and no shares outstanding. As at December 31, 2024, common stock, no par value; 300,000,000 shares authorized and 1,796,766 shares outstanding, and preferred stock, no par value; 30,000,000 share authorized and no shares outstanding (on a post-reverse stock split basis)*.
14
$ 20,174,795
$ 17,332,315
Additional paid in capital
(5,011,891 )
(5,011,891 )
Accumulated deficit
(6,427,227 )
(3,442,620 )
Accumulated other comprehensive losses
(120,749 )
(555,000 )
TOTAL STOCKHOLDERS’ EQUITY
8,614,928
8,322,804
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY
$ 9,252,784
$ 10,433,848
* Issued and outstanding shares of common stock have been adjusted as below:
1) for the periods prior to April 7, 2025, to reflect the 1-for-10 reverse stock split effected on that date on a retroactive basis as described in Note 14.
2) for the periods prior to July 20, 2023, to reflect the 1-for-12 reverse stock split effected on that date on a retroactive basis as described in Note 14
See accompanying notes to the consolidated financial statements.
Read full description ↓
F-7
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME/(LOSS)
FOR THE YEAR ENDED DECEMBER 31, 2025 AND 2024
(Currency expressed in United States Dollars (“US$”))
(Audited)
Year ended
December 31, (Audited)
Consolidated
2025
2024
REVENUE (including $68,104 and $112,556 of revenue from related party for the year ended December 31, 2025 and 2024 respectively)
$ 7,424,911
$ 9,510,646
COST OF REVENUE (including $9,503 and $297,736 of cost of revenue from related party for the year ended December 31, 2025 and 2024, respectively)
(6,339,694 )
(8,221,125 )
GROSS PROFIT
1,085,217
1,289,521
OTHER INCOME
Dividend income
22,112
68,130
Interest income
83,888
147,641
Fair value gain on investments in equity securities
-
69,476
Gain on disposal of investments in equity securities
27,201
38,409
Reversal of expected credit losses
144,767
1,689,412
Gain from foreign exchange
94,664
-
Others
59,485
59,405
TOTAL OTHER INCOME
432,117
2,072,473
OPERATING EXPENSES
Sales and marketing
(1,736,331 )
(2,030,684 )
Research and development
(50,670 )
(47,511 )
General and administrative (including $4,206 and $1,969 of rental expenses to related party for the year ended December 31, 2025 and 2024, respectively)
(1,535,452 )
(1,832,968 )
Share-based compensation
(794,770
)
(141,000
)
Fair value loss on investments in equity securities
(93,965 )
-
Provision for expected credit losses
(271,211 )
(883,533 )
TOTAL OPERATING EXPENSES
(4,482,399 )
(4,935,696 )
LOSS FROM OPERATIONS
(2,965,065 )
(1,573,702 )
FINANCE COSTS
(19,542 )
(21,146 )
LOSS BEFORE TAXES
(2,984,607 )
(1,594,848 )
Tax expense:
Deferred tax
-
12,305
Income tax
-
(15,799 )
Tax expense
-
(3,494 )
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS
$ (2,984,607 )
$ (1,598,342 )
Other comprehensive income
Foreign currency translation gain
434,251
122,294
COMPREHENSIVE LOSS
$ (2,550,356 )
$ (1,476,048 )
Earnings per share - Basic and diluted
(1.607 )
(0.897 )
Weighted average number of common stocks outstanding, Basic and Diluted #
1,856,680
1,781,848
# Weighted average shares outstanding and per share amount have been adjusted for the periods shown to reflect the 1-for-10 reverse stock split effected on April 7, 2025 and the 1-for-12 reverse stock split effected on July 20, 2023, on a retroactive basis as described in Note 14.
See accompanying notes to the consolidated financial statements.
F-8
BIONEXUS GENE LAB CORP
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY
FOR THE YEAR ENDED DECEMBER 31, 2025 AND 2024
(Currency expressed in United States Dollars (“US$”))
(Audited)
Accumulated
Common stock
Additional
other
Total
Number of
paid in
Accumulated
comprehensive
stockholders’
shares
Amount
capital
deficit
losses
equity
Balance as of December 31, 2023 *
1,766,766
$ 17,191,315
$ (5,011,891 )
$ (1,844,278 )
$ (677,294 )
$ 9,657,852
Net loss for the year
-
-
-
(1,598,342 )
-
(1,598,342 )
Issuance of shares *
30,000
141,000
-
-
141,000
Foreign currency translation gain
-
-
-
-
122,294
122,294
Balance as of December 31, 2024 *
1,796,766
$ 17,332,315
$ (5,011,891 )
$ (3,442,620 )
$ (555,000 )
$ 8,322,804
Accumulated
Common stock
Additional
other
Total
Number of
paid in
Accumulated
comprehensive
stockholders’
shares
Amount
capital
deficit
losses
equity
Balance as of December 31, 2024 *
1,796,766
$ 17,332,315
$ (5,011,891 )
$ (3,442,620 )
$ (555,000 )
$ 8,322,804
Net loss for the year
-
-
-
(2,984,607 )
-
(2,984,607 )
Issuance of shares
620,548
2,842,480
-
-
-
2,842,480
Foreign currency translation gain
-
-
-
-
434,251
434,251
Balance as of December 31, 2025 *
2,417,314
$ 20,174,795
$ (5,011,891 )
$ (6,427,227 )
$ (120,749 )
$ 8,614,928
* Share activity (number of shares or both number and amount of shares) has been adjusted for the periods shown to reflect the 1-for-10 reverse stock split effected on April 7, 2025, on a retroactive basis
See accompanying notes to the consolidated financial statements.
F-9
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE YEAR ENDED DECEMBER 31, 2025 AND 2024
(Currency expressed in United States Dollars (“US$”))
(Audited)
Year ended
December 31,
2025
2024
Cash flows from operating activities:
Net loss
$ (2,984,607 )
$ (1,598,342 )
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of right-of-use asset
56,434
48,983
Allowances for expected credit losses
271,211
883,533
Recoveries for expected credit losses
(144,767 )
(1,689,412 )
Bad debts written off
-
6,344
Depreciation of property, plant and equipment
111,873
104,160
Dividend income
(22,112 )
(68,130 )
Fair value loss/(gain) on investments in equity securities
93,965
(69,476 )
Loss arising from settlement of supplier contract dispute
-
29,534
Gain on disposal of investments in equity securities
(27,201 )
(38,409 )
Loss on lease termination
-
1,384
Impairment on property
-
40,173
Share-based compensation
794,770
141,000
Operating loss before working capital changes
(1,850,434 )
(2,208,658 )
Changes in operating assets and liabilities:
Inventories
711,921
(250,854 )
Trade, other receivables and other assets
782,841
147,760
Trade and other payables
(1,383,488 )
204,342
Advance payment from customer
(87,494 )
95,879
Operating lease liabilities
(34,511 )
(42,895 )
Tax recoverable/(liabilities)
22,783
(38,834 )
Net cash used in operating activities
(1,838,382 )
(2,093,260 )
Cash flows from investing activities:
Acquisition of investments in equity securities
(9,159 )
(492,732 )
Dividend income
22,112
68,130
Change in fixed deposits placed with original maturities more than three months
(62,860 )
(78,835 )
Purchase of plant and equipment
(36,971 )
(226,989 )
Proceeds from disposal of investments in equity securities
1,031,629
1,068,777
Proceeds from settlement of supplier contract dispute
-
79,851
Net cash generated from investing activities
944,751
418,202
F-10
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE YEAR ENDED DECEMBER 31, 2025 AND 2024
(Currency expressed in United States Dollars (“US$”))(CONT’D)
(Audited)
Year ended
December 31,
2025
2024
Cash flows from financing activities:
Advances from directors
32,305
3,975
Cash paid for fractional shares in reverse stock split
(775 )
-
Share subscription
267,311
-
Net cash generated from financing activities
298,841
3,975
Foreign currency translation adjustment
194,207
40,339
NET CHANGE IN CASH AND CASH EQUIVALENTS
(400,583 )
(1,630,744 )
CASH AND CASH EQUIVALENTS, BEGINNING OF FINANCIAL YEAR
2,886,966
4,517,710
CASH AND CASH EQUIVALENTS, END OF FINANCIAL YEAR
$ 2,486,383
$ 2,886,966
CASH AND CASH EQUIVALENTS INFORMATION:
Fixed deposits placed with financial institutions with original maturities of three months or less
$ 103,014
$ 1,303,487
Cash and bank balances
2,383,369
1,583,479
Cash and cash equivalents, end of financial year
2,486,383
2,886,966
Supplementary cash flow information:
Interest paid
$ (6,865 )
$ (9,351 )
Income tax refunded
43,655
-
Income tax paid
(14,823 )
(40,380 )
Acquisition of investment via share exchange
(1,781,174
)
-
See accompanying notes to the consolidated financial statements.
F-11
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED DECEMBER 31, 2025 AND 2024
(Currency expressed in United States Dollars (“US$”))
(Audited)
NOTE 1 – ORGANIZATION AND BUSINESS BACKGROUND
BioNexus Gene Lab Corp. (the “Company”) was incorporated in the State of Wyoming on May 12, 2017. On August 23, 2017, the Company acquired all the outstanding capital stock of BioNexus Gene Lab Sdn. Bhd., incorporated in Malaysia on April 7, 2015 which then subsequently changed its name to MRNA Scientific Sdn. Bhd. (MRNA Scientific) on September 19, 2023.
The principal office address is Unit A-28-7, Level 28, Tower A, Menara UOA Bangsar, No.5 Jalan Bangsar Utama 1, Kuala Lumpur, Malaysia, our lab is located at Lab 353, Chemical Science Centre, University Science Malaysia, George Town, Penang, Malaysia. We also have a blood collection center located at 1st floor, Lifecare Medical Centre, Kuala Lumpur, Malaysia.
On December 31, 2020, the Company consummated its acquisition of Chemrex Corporation Sdn. Bhd. (“Chemrex”), pursuant to a Share Exchange Agreement by and among the Company, Chemrex and the Chemrex shareholders wherein the Company acquired all the issued and outstanding shares of capital stock of Chemrex from the Chemrex shareholders in exchange for 68,487,261 shares of common stock of the Company.
The acquisition of Chemrex has been accounted for as a common control transaction as there is no change in the control over the assets acquired and liabilities assumed. The net assets are derecognized by the transferring entity (i.e. Chemrex) and recognized by the receiving entity (i.e. the Company). The difference between the consideration transferred and the carrying amounts of the net assets is recognized in equity.
The financial statements of the receiving entity report the results of operations for the period in which the transfer occurs as though the transfer of net assets or exchange of equity interests had occurred at the beginning of the period. Results of operations for that period will thus comprise those of the previously separate entities combined from the beginning of the period to the date the transfer is completed and those of the combined operations from that date to the end of the period. The comparative financial statements were not adjusted retrospectively as Chemrex was not under common control during the comparative period.
The corporate structure as at December 31, 2025 is depicted below:
BioNexus Gene Lab Corp.
a Wyoming company
100% owned
100% owned
MRNA Scientific Sdn. Bhd.
Chemrex Corporation Sdn. Bhd.,
(formerly known as “BioNexus Gene Lab Sdn. Bhd.”),
a Malaysian Company
a Malaysian company
F-12
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED DECEMBER 31, 2025 AND 2024
(Currency expressed in United States Dollars (“US$”))
(Audited)
NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
The accompanying consolidated financial statements reflect the application of certain significant accounting policies as described in this note and elsewhere in the accompanying consolidated financial statements and notes.
☐ Basis of presentation
The accompanying consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”).
☐ Basis of consolidation
The consolidated financial statements include the accounts of BioNexus Gene Lab Corp. and its subsidiaries. Acquired businesses are included in the consolidated financial statements from the dates of acquisition. The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. All inter-company accounts and transactions have been eliminated in consolidation.
☐ Going concern
The accompanying consolidated financial statements have been prepared on a going concern basis which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying consolidated financial statements, for the year ended December 31, 2025, the Company recorded a net loss of $2,984,607 and negative cash outflows from operating activities of $1,838,382 and as of December 31, 2025, the Company incurred an accumulated deficit of $6,427,227. These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the financial statements are issued. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.
The Company’s ability to continue as a going concern is dependent upon improving its profitability and the ability secure external financing and fundraising. Management believes the external financing or fundraising will provide additional cash to meet the Company’s obligations as they become due. No assurance can be given that any future financing, if needed, will be available or, if available, that it will be on terms that are satisfactory to the Company. Even if the Company can obtain additional financing, if needed, it may contain undue restrictions on its operations, in the case of debt financing, or cause substantial dilution for its stockholders, in the case of equity financing.
☐ Use of estimates
The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions relating to the reporting of assets and liabilities and the disclosure of contingent liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant accounting estimates include certain assumptions related to allowance for credit losses for financial assets and impairment analysis of long-lived assets. Actual results may differ from these estimates.
☐ Cash and cash equivalents
Cash and cash equivalents represent cash on hand, demand deposits placed with banks or other financial institutions and all highly liquid investments with an original maturity of three months or less as of the purchase date of such investments.
The Company maintains cash balances with multiple financial institutions in Malaysia as well as in the United States. Deposits placed with each institution in Malaysia are insured by the Malaysia Deposit Insurance Corporation (Perbadanan Insurans Deposit Malaysia, or PIDM) up to RM250,000 (approximately USD 58,000) per depositor. While for deposits placed with institution in the United States, it is insured by the Federal Deposit Insurance Corporation (FDIC) up to USD250,000 per depositor, per insured bank, for each account ownership category under the FDIC's general deposit insurance rules.
From time to time, the Company’s cash balances may exceed these insured limits. As of December 31, 2025, cash balances exceeding the insured limit amounted to $2,050,790. However, the Company has not experienced any losses on such accounts and believes that its exposure to credit risk is not significant. The Company actively monitors its balances with these financial institutions and considers the risk of loss to be remote.
☐ Trade receivables
Trade receivables are recorded at the invoiced amount and are generally non-interest bearing. However, interest may be imposed on extended credit terms or overdue balances. The Company recognizes an allowance for credit losses in accordance with ASC 326, Financial Instruments – Credit Losses, using an expected credit loss (ECL) model.
The allowance for credit losses is measured based on historical collection experience, aging of receivables, customer-specific credit risk, and current and expected future economic conditions. The Company disaggregates its trade receivables by customer type, as management has determined that risk profiles vary based on the industry and nature of the customer. For each customer type, the Company applies a historical loss rate matrix, adjusted for forward-looking information and macroeconomic trends relevant to the industries in which customers operate.
In addition to the collective assessment, specific allowances are established for customers with known financial difficulties or higher risk of default, based on a review of individual outstanding invoices and relevant credit information.
Trade receivables are written off against the allowance when all reasonable collection efforts have been exhausted and recovery is considered remote. The allowance for credit losses is recorded as a contra-asset account to trade receivables in the consolidated balance sheets, and changes to the allowance are recognized in the consolidated statement of operations and comprehensive income/(loss).
F-13
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED DECEMBER 31, 2025 AND 2024
(Currency expressed in United States Dollars (“US$”))
(Audited)
☐ Inventories
Inventories consisting of products available for sale are stated at the lower of cost or net realizable value. Cost of inventory is determined using the first-in, first-out (FIFO) method. Inventory reserve is recorded to write down the cost of inventory to the estimated net realizable value due to slow-moving merchandise and damaged goods, which is dependent upon factors such as historical and forecasted consumer demand, and promotional environment. The Company takes ownership, risks, and rewards of the products purchased. Write downs are recorded in cost of revenues in the Consolidated Statement of Operations and Comprehensive Income/(Loss).
☐ Leases
The Company determines if a contract is or contains a lease at the inception of the contract or modification of the contract. A contract is or contains a lease if the contract conveys the right to control the use of an identified asset for a period in exchange for consideration. Control over the use of the identified asset means the lessee has both (a) the right to obtain substantially all of the economic benefits from the use of the asset and (b) the right to direct the use of the asset.
Finance and operating lease right-of-use (“ROU”) assets and liabilities are recognized based on the present value of future minimum lease payments over the expected lease term at commencement date. As the implicit rate is not determinable in most of the Company’s leases, management uses the Company’s incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The expected lease term includes options to extend or terminate the lease when it is reasonably certain the Company will exercise the option. Lease expense for minimum lease payments is recognized on a straight-line basis over the expected lease term.
The Company’s lease arrangements have lease and non-lease components. Leases with an expected term of 12 months or less are not accounted for on the balance sheet and the related lease expense is recognized on a straight-line basis over the expected lease term.
☐ Property, plant and equipment
Property, plant and equipment are stated at cost less accumulated depreciation and accumulated impairment losses, if any. Depreciation is calculated on the straight-line basis to write off the cost over the following expected useful lives of the assets concerned. The principal annual rates used are as follows:
Principal
Categories
Annual Rates
Air conditioner
20 %
Buildings
2 %
Computer and software
33 %
Equipment
20 %
Furniture and fittings
10% to 20
%
Lab Equipment
10 %
Motor vehicle
10% to 20
%
Office equipment
20 %
Renovation
10% to 20
%
Signboard
10 %
Solar PV System
20 %
Machinery
10 %
Leasehold lands are depreciated over the period of lease term. Leased assets are depreciated over the shorter of the lease term and their useful lives unless it is reasonably certain that the Company will obtain ownership by the end of the lease term. Freehold land is not depreciated. Property, plant and equipment under construction are not depreciated until the assets are ready for their intended use.
Maintenance and repairs are charged to operations as incurred. Expenditures which substantially increase the useful lives of the related assets are capitalized. When properties are disposed of, the related costs and accumulated depreciation are removed from the accounts and any gain or loss is reported in the period the transaction takes place.
Fully depreciated plant and equipment are retained in the financial statements until they are no longer in use.
F-14
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED DECEMBER 31, 2025 AND 2024
(Currency expressed in United States Dollars (“US$”))
(Audited)
☐ Investments in equity securities
The Company accounts for its investments that represent less than 20% ownership, and for which the Company does not have the ability to exercise significant influence, using ASC 321, Investments—Equity Securities. Equity securities with readily determinable fair values are measured at fair value, with changes in fair value recognized in net income. These investments are classified within “Investments in equity securities” on the consolidated balance sheets, and unrealized gains and losses are included in “Other income (expense), net” in the consolidated statement of operations and comprehensive income/(loss).
For equity securities without readily determinable fair values, the Company may elect the practicability exception to measure such investments at cost, less impairment, if any, plus or minus observable price changes in orderly transactions for the identical or a similar investment of the same issuer. These securities are evaluated at each reporting period for impairment or observable price changes.
Realized gains and losses on sales of equity securities are determined based on the specific identification method and are also recorded in net income.
☐ Impairment of long-lived assets
Long-lived assets primarily include goodwill, intangible assets and property, plant and equipment. In accordance with the provision of ASC Topic 360, “Impairment or Disposal of Long-Lived Assets”, the Company generally conducts its annual impairment evaluation to its long-lived assets, usually in the fourth quarter of each fiscal year, or more frequently if indicators of impairment exist, such as a significant sustained change in the business climate. The recoverability of long-lived assets is measured at the lowest level group. If the total of the expected undiscounted future net cash flows is less than the carrying amount of the asset, a loss is recognized for the difference between the fair value and carrying amount of the asset. There has been no impairment charge for the years presented.
☐ Revenue recognition
Revenues are recognized when control of the promised goods or services are transferred to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services.
The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements:
·
identify the contract with a customer;
·
identify the performance obligations in the contract;
·
determine the transaction price;
·
allocate the transaction price to performance obligations in the contract; and
·
recognize revenue as the performance obligation is satisfied.
The Company records revenue at point in time which is recognized upon goods delivered or services rendered.
☐ Shipping and handling fees
Shipping and handling fees, if billed to customers, are included in revenue. Shipping ang handling fees associated with inbound and outbound freight are expensed as incurred and included in selling and distribution expenses.
☐ Comprehensive income
ASC Topic 220, “Comprehensive Income” establishes standards for reporting and display of comprehensive income, its components and accumulated balances. Comprehensive income as defined includes all changes in equity during a period from non-owner sources. Accumulated other comprehensive income, as presented in the accompanying statements of stockholders’ equity consists of changes in unrealized gains and losses on foreign currency translation and cumulative net change in the fair value of available-for-sale investments held at the balance sheet date. This comprehensive income is not included in the computation of income tax expense or benefit.
☐ Income taxes
Income taxes are determined in accordance with the provisions of ASC Topic 740, “Income Taxes” (“ASC Topic 740”). Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted income tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Any effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.
F-15
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED DECEMBER 31, 2025 AND 2024
(Currency expressed in United States Dollars (“US$”))
(Audited)
ASC 740 prescribes a comprehensive model for how companies should recognize, measure, present, and disclosed in their financial statements uncertain tax positions taken or expected to be taken on a tax return. Under ASC 740, tax positions must initially be recognized in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions must initially and subsequently be measured as the largest amount of tax benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority assuming full knowledge of the position and relevant facts.
The Company conducts major businesses in Malaysia and is subject to tax in their own jurisdictions. As a result of its business activities, the Company will file separate tax returns that are subject to examination by the foreign tax authorities.
☐ Net earnings or loss per share
The Company calculates net earnings or loss per share in accordance with ASC Topic 260 “Earnings per share”. Basic earnings or loss per share is computed by dividing the net earnings or loss by the weighted average number of common shares outstanding during the period. Diluted earnings or loss per share is computed similar to basic earnings or loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common stock equivalents had been issued and if the additional common shares were dilutive.
☐ Foreign currencies translation
Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency using the applicable exchange rates at the balance sheet dates. The resulting exchange differences are recorded in the statement of operations.
The functional currency of the Company is the United States Dollars (“US$”) and the accompanying financial statements have been expressed in US$ as being the primary currency of the economic environment in which the Company operates. The functional currency of the subsidiaries is Malaysian Ringgit (“MYR”) as being the primary currency of the economic environment in which the subsidiaries operate.
In general, for consolidation purposes, assets and liabilities of its subsidiaries whose functional currency is not US$ are translated into US$, in accordance with ASC Topic 830-30, “Translation of Financial Statement”, using the exchange rate on the balance sheet date. Revenues and expenses are translated at average rates prevailing during the period. The gains and losses resulting from translation of financial statements of foreign subsidiaries are recorded as a separate component of accumulated other comprehensive income.
Translation of amounts from RM (MYR) into US$1.00 has been made at the following exchange rates for the respective years:
December 31,
December 31,
2025
2024
Year-end US$1.00: MYR exchange rate
4.0610
4.4755
January 1,
January 1,
2025 to
2024 to
December 31,
December 31,
2025
2024
Yearly average US$1.00: MYR exchange rate
4.2799
4.5710
F-16
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED DECEMBER 31, 2025 AND 2024
(Currency expressed in United States Dollars (“US$”))
(Audited)
☐ Related parties
Parties, which can be a corporation or individual, are related if the Company has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions. Companies are also considered to be related if they are subject to common control or common significant influence.
☐ Fair value of financial instruments
The Company follows the guidance of the ASC Topic 820-10, “Fair Value Measurements and Disclosures” ("ASC 820-10"), with respect to financial assets and liabilities that are measured at fair value. ASC 820-10 establishes a three-tier fair value hierarchy that prioritizes the inputs used in measuring fair value as follows:
·
Level 1 : Observable inputs such as quoted prices in active markets;
·
Level 2 : Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and
·
Level 3 : Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions
The carrying value of the Company’s financial instruments: cash and bank balances, fixed deposits placed with financial institutions, trade receivable, other receivables, deposits, trade payables, other payables and accrued liabilities, advance payment from customers and amount owing to directors approximate at their fair values because of the short-term nature of these financial instruments
As of December 31, 2025, and December 31, 2024, the Company did not have any non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements, at least annually, on a recurring basis, nor did the Company have any assets or liabilities measured at fair value on a non-recurring basis.
☐ Recent accounting pronouncements
The Company has reviewed all recently issued, but not yet effective, considers the applicability and impact of all accounting standards updates (“ASUs”).
Management periodically reviews new accounting standards that are issued.
F-17
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED DECEMBER 31, 2025 AND 2024
(Currency expressed in United States Dollars (“US$”))
(Audited)
Accounting Standards Adopted in 2025
Accounting Standards Update 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures:
In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The new standard was issued to improve transparency and decision usefulness of income tax disclosures by providing information that helps investors better understand how an entity’s operations, tax risks, tax planning and operational opportunities affect its tax rate and prospects for future cash flows. The amendments in this update primarily relate to requiring greater disaggregated disclosure of information in the rate reconciliation, income taxes paid, income (loss) from continuing operations before income tax expense (benefit), and income tax expense (benefit) from continuing operations. The ASU is effective for fiscal years beginning after December 15, 2024, and early adoption is permitted. The standard can be applied prospectively or retrospectively. The Company adopted this ASU prospectively in the fourth quarter of 2025, and the required disclosures are included in Note 15, Income Taxes.
Accounting Standards not yet Adopted
Accounting Standards Update 2024-03, Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40):
Disaggregation of Income Statement Expenses:
In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses. The new standard requires entities to disclose additional information about certain expenses, such as purchases of inventory, employee compensation, depreciation, intangible asset amortization, as well as selling expenses included in commonly presented expense captions on the income statement. The FASB further clarified the effective date in January 2025 with the issuance of ASU 2025-01, Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date. The ASU is effective for fiscal years beginning after December 15, 2026, and interim periods beginning after December 15, 2027. Companies have the option to apply this guidance either on a retrospective or prospective basis, and early adoption is permitted.
The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements and related disclosures.
The Company does not expect that any other recently issued accounting pronouncements will have a significant effect on its consolidated financial statements.
F-18
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED DECEMBER 31, 2025 AND 2024
(Currency expressed in United States Dollars (“US$”))
(Audited)
NOTE 3 – TRADE RECEIVABLES
The Company’s trade receivables represent amounts due from customers that are unrelated parties and related parties of $31,420 and $47,272 for year 2025 and 2024 respectively. Trade receivables are initially recognized at the invoiced amount and subsequently measured at amortized cost, net of an allowance for expected credit losses. An estimate for doubtful debts is made when collection of the full amount is no longer probable. Trade receivables are written off when they are determined to be uncollectible, and all reasonable collection efforts have been exhausted.
As of December 31, 2025, the Company performed an analysis of all outstanding trade receivables in accordance with the expected credit loss model under ASC 326. The Company considered historical collection trends, aging of balances, customer credit profiles, and current and forecasted economic conditions in estimating the allowance.
The Company’s standard credit terms range from 30 to 90 days. Certain receivables are interest-bearing. Specifically, Intralink Techno was charged with interest at 6% per annum from May 2021 to June 2023. From July 2023 onwards, the Company increased its interest rate to 8.4%.
As of
December 31,
December 31,
2025
2024
Trade receivables
1,209,880
1,894,448
Allowances for expected credit losses
(703,995 )
(517,877 )
Total trade receivables, net
$ 505,885
$ 1,376,571
Movement for trade receivables allowance for impairment accounts:
As of
December 31,
December 31,
2025
2024
At January 1, 2025 and January 1, 2024
517,877
1,307,508
Charge for the year
Allowances for expected credit losses
225,756
883,533
Recovered for expected credit losses
(97,203 )
(1,689,412 )
Foreign translation differences
57,565
16,248
At December 31, 2025 and 2024
$ 703,995
$ 517,877
F-19
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED DECEMBER 31, 2025 AND 2024
(Currency expressed in United States Dollars (“US$”))
(Audited)
NOTE 4 – OTHER ASSETS
On November 28, 2025, the Company entered into an Exclusive Intellectual Property License Agreement (the “License Agreement”) with Fidelion Diagnostics Pte. Ltd. (“Fidelion”), pursuant to which the Company received an exclusive, irrevocable license to use, develop, manufacture, market, distribute, and sell products utilizing the VitaGuard™ minimal residual disease (“MRD”) liquid biopsy platform in the member states of the Association of Southeast Asian Nations (“Southeast Asia” or the “Territory”).
In consideration for the license, the Company agreed to pay Fidelion a total license fee of $2,000,000 in 24 equal monthly instalments. Other Assets comprises the first instalment payment toward the licensing agreement.
NOTE 5 – INCOME TAXES
Loss before income taxes for the years ended December 31, 2025, and 2024 is summarized as follows:
Year ended December 31,
2025
2024
Loss before income taxes:
Local
$ (1,709,197 )
$ (1,144,817 )
Foreign, representing Malaysia
(1,275,410 )
(450,031 )
$ (2,984,607 )
$ (1,594,848 )
Provision for income taxes for the years ended December 31, 2025, and 2024 is summarized as follows:
Year ended December 31,
2025
2024
Current (expense)/benefit:
Federal
$ -
$ -
Local
-
-
Foreign, representing Malaysia
-
(15,799 )
Total current
-
(15,799 )
Deferred (expense)/benefit:
Federal
-
-
Local
-
-
Foreign, representing Malaysia
-
12,305
Total deferred
-
12,305
Total deferred benefit
$ -
$ (3,494 )
The income taxes paid (net of refunds) by jurisdiction for the years ended December 31, 2025, and 2024, as reported in the Consolidated Statements of Cash Flows, are as follows:
Year ended December 31,
2025
2024
U.S. federal
$ -
$ -
Foreign, representing Malaysia
$ (28,832 )
$ 40,380
Total income taxes paid/(refunded), net
$ (28,832 )
$ 40,380
The reconciliation of the federal statutory income tax amount and rate to the Company’s effective tax rate for the years ended December 31, 2025, and 2024 is as follows:
Year ended December 31,
2025
2024
Amount
%
Amount
%
Loss before income taxes
$ (2,984,607 )
$ (1,594,848 )
Federal statutory tax rate
(626,767
)
21.00
%
(334,924
)
21.00
%
State and local income tax, net of federal income tax effect
-
-
-
-
Foreign tax effects:
Malaysia
Foreign rate difference
(38,262
)
1.28
%
(13,494
)
0.85
%
Non-taxable or non-deductible items
186,128
-6.24
%
(149,821
)
9.39
%
Prior year tax adjustment
-
-
20,531
-1.29
%
Changes in valuation allowances
478,902
-16.05
%
481,201
-30.17
%
Income tax expense and effective tax rate
$ -
-
$ 3,494
-0.22
%
F-20
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED DECEMBER 31, 2025 AND 2024
(Currency expressed in United States Dollars (“US$”))
(Audited)
The significant components of deferred taxes of the Company are as follows
As of December 31,
2025
2024
Deferred tax assets
Property, plant and equipment
$
(214,436
)
(179,429
)
Capital allowances
315,688
204,398
Net operating loss (NOL) carryforwards:
– United States of America
8,938,122
8,024,108
– Malaysia
2,567,801
1,354,566
Gross deferred tax assets
11,607,175
9,403,642
Less: Valuation allowance
(11,607,175
)
(9,403,642
)
Deferred tax assets, net of valuation allowance
-
-
The table below summarizes changes in the valuation allowance for deferred tax assets for the years presented:
Year ended December 31,
2,025
2,024
Valuation allowance
Balance, beginning of year
$ 9,403,642
$ 7,267,659
Increases in (reversal of) valuation allowance during the year
2,203,533
2,135,984
Balance, end of year
$ 11,607,175
$ 9,403,642
The Company believes that it is more likely than not that the deferred tax assets will not be fully realized in the future. Accordingly, the Company established a valuation allowance of 11,607,175 to offset deferred tax assets of $11,607,175 including deferred tax assets related to the net operating loss (NOL) carry forwards of $11,505,923 as of December 31, 2025.
For the year ended December 31, 2025, a valuation allowance was increased by $2,203,533, this increase was primarily due to an increase of NOL carryforwards of $1,213,235 from the Company’s Malaysia subsidiaries.
United States of America
The Company is registered in the State of Wyoming and is subject to United States of America tax law.
For the years ended December 31, 2025, and 2024, the operations in the United States of America incurred a net operating loss (NOL) of $1,709,197 and $1,144,817, respectively.
As of December 31, 2025, the cumulative net operating losses (NOLs) were $8,938,122 which can be carried forward to offset future taxable income. The NOL carryforwards begin to expire in 2041, if unutilized.
Malaysia
The Company’s subsidiaries operating in Malaysia are subject to the Malaysia Corporate Tax Laws at a standard income tax rate of 24% on their assessable income for the tax year.
For the years ended December 31, 2025, and 2024, the subsidiaries in Malaysia incurred an aggregate net operating loss (NOL) of $1,275,410 and $450,031, respectively
As of December 31, 2025, the operations in Malaysia had incurred the aggregate amount of cumulative net operating losses (NOLs) of $2,567,801 which can be carried forward carried forward indefinitely to offset taxable income in the future. The NOL carryforwards begins to expire in 2029, if unutilized.
F-21
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED DECEMBER 31, 2025 AND 2024
(Currency expressed in United States Dollars (“US$”))
(Audited)
NOTE 6 – OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITIES
The Company has operating lease arrangements for office space, lab, and motor vehicles in Malaysia with a term between two and five years, generally with option to renew the lease after that date. The Company accounts for the lease and non-lease components of its leases as a single lease component. Lease expense is recognized on a straight-line basis over the lease term.
Operating lease right-of-use assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term.
The present value of the lease payments are discounted with rates ranging from 6.40% to 6.65% per annum. These rates are reference from base rate of Malayan Banking Berhad, the largest bank in Malaysia.
As of December 31, 2025 and 2024 operating lease right-of-use assets as follows:
As of
December 31,
December 31,
2025
2024
Balance as of December 31, 2024
$ 215,243
$ 141,544
Add: Addition of right of use assets (1)
-
145,736
Less: amortization (2)
(56,434 )
(48,983 )
Less: lease termination (3)
-
(25,093 )
Foreign translation differences
18,928
2,039
Balance as of December 31, 2025
$ 177,737
$ 215,243
As of December 31, 2025 and 2024 operating lease liabilities as follows:
As of
December 31,
December 31,
2025
2024
Balance as of beginning of the year
$ 210,557
$ 133,395
Add: addition of lease liabilities (1)
-
145,736
Less: gross repayment
(65,817 )
(56,598 )
Add: imputed interest (4)
12,677
11,795
Less: lease termination (3)
-
(25,679 )
Foreign translation differences
18,629
1,908
Balance as of end of the year
176,046
210,557
Less: lease liability current portion
(59,147 )
(50,816 )
Lease liability non-current portion
$ 116,899
$ 159,741
F-22
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED DECEMBER 31, 2025 AND 2024
(Currency expressed in United States Dollars (“US$”))
(Audited)
As of December 31, 2025 and 2024, the maturities of the operating lease liabilities are as follows:
As of
December 31,
December 31,
2025
2024
Years ending December 31 and December 31:
2025
-
62,939
2026
68,671
62,311
2027
61,058
55,403
2028
49,776
45,166
2029
14,159
12,848
Total undiscounted cash flows
193,664
238,667
Less: Interest imputed on lease liabilities
(17,618 )
(28,110 )
Present value of lease liabilities
$ 176,046
$ 210,557
(1) During the year ended December 31, 2024, the Company entered into a new operating lease of office space in Malaysia for 5 years. Additional right-of-use assets at $131,581 and lease liabilities at $131,581 were recognised upon the commencement of lease term. The Company also renewed the lease for the lab in Penang, Malaysia, for 2 years, with additional right-of-use assets of $14,155 and lease liabilities of $14,155 recognised upon the commencement of lease term.
(2) The amortization of the operating lease right-of-use asset for the year ended December 31, 2025 and 2024 were $56,434 and $48,983, respectively.
(3) The Company agreed to terminate its operating lease arrangement for office space in Malaysia, effective August 31, 2024. Accordingly, at the date of termination of the operating lease, the Company expensed a right-of-use-asset, net of accumulated depreciation, of $25,094 and recorded a write-off of lease liability of $25,679, with a loss on lease termination recorded for $1,384.
As of
December 31,
December 31,
2025
2024
Supplemental Cash Flow Disclosures:
Cash paid for amounts included in the measurement of lease liabilities:
Lease payment – operating leases
$ (65,817 )
$ (56,598 )
Operating lease liabilities obtained in exchange for operating lease assets
-
145,736
Other information:
Weighted average remaining lease term for operating lease (years)
3.42
4.42
Weighted average discount rate for operating lease
6.65 %
6.65 %
(4) Lease expenses for the year ended December 31, 2025 and 2024 were $69,111 and $60,778 respectively.
Other information:
As of
December 31,
December 31,
2025
2024
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flow from operating lease
$ (34,511 )
$ (42,895 )
Right of use assets obtained in exchange for operating lease liabilities
177,737
215,243
Remaining lease term for operating lease (years)
3.42
4.42
Weighted average discount rate for operating lease
6.65 %
6.65 %
F-23
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED DECEMBER 31, 2025 AND 2024
(Currency expressed in United States Dollars (“US$”))
(Audited)
NOTE 7 – PROPERTY, PLANT AND EQUIPMENT
Property, plant and equipment consisted of the following:
As of
December 31,
December 31,
2025
2024
Air conditioner
$ 1,124
$ 1,124
Computer and software
7,262
5,880
Equipment
65,360
65,214
Furniture and fittings
98,883
98,883
Lab equipment
320,102
320,102
Land and buildings
1,506,969
1,506,969
Motor vehicle
161,148
161,148
Office equipment
41,108
37,604
Renovation
111,519
101,137
Signboard
806
806
Solar PV System
16,935
16,935
Machinery
211,898
190,341
2,543,114
2,506,143
(Less): Accumulated depreciation
(868,849 )
(756,976 )
(Less): Accumulated impairment
(40,173 )
(40,173 )
Add: Foreign translation differences
(35,323 )
(186,004 )
Property, plant and equipment, net
$ 1,598,769
$ 1,522,990
During the year ended December 31, 2025 and 2024, the Company recorded depreciation of $111,873 and $104,160, respectively.
F-24
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED DECEMBER 31, 2025 AND 2024
(Currency expressed in United States Dollars (“US$”))
(Audited)
NOTE 8 – INVESTMENTS IN EQUITY SECURITIES
As of
December 31,
December 31,
2025
2024
As of beginning of the year
$ 1,265,166
$ 1,699,831
Addition during the year
1,790,333
492,732
Disposal during the year
(1,004,428 )
(1,030,368 )
Fair value (loss)/gain
(93,965 )
69,476
Foreign exchange translation
70,434
33,495
As of end of the year
$ 2,027,540
$ 1,265,166
For the year ended December 31, 2025 and 2024, the net fair value (loss)/gains on the investments in equity securities were $(93,965) and $69,476 recorded in other income of the Consolidated Statements of Operations and Comprehensive Income/(Loss).
The investments in equity securities consist of the following shares:
As of
December 31,
December 31,
2025
2024
Investment in equity securities with readily determined fair value:
Malaysia
-
863,810
Singapore
-
177,808
$ -
$ 1,041,618
Investment in equity securities without readily determined fair value:
Malaysia
246,366
223,548
Singapore
1,781,174
-
$ 2,027,540
$ 1,265,166
Equity Securities With Readily Determinable Fair Value
The Company’s investment in equity securities total of $Nil and$1,041,618 as of December 31, 2025 and 2024 respectively, are measured at fair value on a recurring basis. These equity securities are classified as Level 1 in the fair value hierarchy, as the fair value is determined using quoted market prices in active markets for identical assets. Specifically, the stock prices of these securities are readily available on the stock exchange, providing a reliable and observable input to the fair value measurement.
As these securities are actively traded, the quoted prices in the market are considered to be the most reliable indicator of fair value. No significant adjustments are made to these prices, as they reflect current market conditions at the measurement date.
Equity Securities Without Readily Determinable Fair Values
The Company’s investments in equity securities without readily determinable fair values consist of investments in privately held companies and totaled $2,027,540 and $223,548 as of December 31, 2025 and 2024, respectively.
These investments are accounted for in accordance with ASC 321, Investments—Equity Securities, using the measurement alternative, under which such securities are measured at cost, less impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer.
The Company evaluates these investments for impairment on a quarterly basis by performing a qualitative assessment to determine whether the fair value of an investment is less than its carrying amount. If an impairment is identified, the investment is written down to its fair value, with the loss recognized in earnings. In addition, the carrying value of these investments is adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer.
Because these investments are in privately held companies and lack observable market prices, the determination of fair value for impairment assessments requires significant judgment. When such investments are remeasured due to impairment or observable price changes, the resulting fair value measurements are classified within Level 3 of the fair value hierarchy.
For year 2025, the Company issued 392,329 shares of common stock at value of $1,781,174 to Fidelion Diagnostics Pte. Ltd (“Fidelion”) as consideration for the Company’s subscription of Fidelion shares. This form part of the condition under the Share Subscription and Shareholders’ Agreement “SSSA” entered into with Fidelion and TongShu Biotechnology (Hong Kong) Co., Limited (‘Tongshu”)
F-25
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED DECEMBER 31, 2025 AND 2024
(Currency expressed in United States Dollars (“US$”))
(Audited)
NOTE 9 – TRADE PAYABLES
Trade payables are amounts billed to the Company by suppliers for goods and services in the ordinary course of business. All amounts have short-term repayment terms and vary by supplier.
NOTE 10 – OTHER PAYABLES AND ACCRUED LIABILITIES
Other payables comprised mainly amounts owing to service provider and first instalment payment due to Fidelion relating the licensing agreement at $83,333. All amounts have short payment terms.
2025
2024
$
$
Other payables
275,574
115,356
Accrued liabilities
126,036
168,752
401,611
284,108
NOTE 11 – REVENUE
The following table shows disaggregated net revenue from contracts with customers by product or service line and geographic area for the year ended December 31, 2025 and 2024:
For the year ended
December 31,
December 31,
2025
2024
Revenue by product or service line:
Trading of industrial chemicals
7,405,822
9,494,577
Screening services and related sales
19,089
16,069
Net revenue
$ 7,424,911
$ 9,510,646
Revenue by geographic area
Bangladesh
106,253
123,267
Malaysia
5,829,401
7,455,906
Maldives
680,994
762,144
Singapore
240,757
572,027
Sri Lanka
452,639
459,002
Indonesia
114,867
138,300
Net revenue
$ 7,424,911
$ 9,510,646
Timing of recognition:
At a point in time
$ 7,424,911
$ 9,510,646
Revenue is derived from the sale of industrial chemicals and the provision of genomic screening services. Revenue from the sale of goods is recognized at a point in time when control of the goods is transferred to the customer. Credit terms are generally from 30 to 90 days. The Company allows returns only for exchanges with new goods. No warranties are given on the sale of goods.
Revenue from services is recognized at a point in time when the final report is delivered to the customer. Credit terms for these services are generally from 30 days to 60 days. No warranties are given on the services rendered.
In applying ASC 606, the Company does not exercise significant judgment in determining whether revenue from the sale of goods and services should be recognized at a point in time. The criteria for recognizing revenue at a point in time, such as the transfer of control of goods or completion of services, are clear and are based on established contract terms. Therefore, no significant judgment is required in determining the timing of revenue recognition.
F-26
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED DECEMBER 31, 2025 AND 2024
(Currency expressed in United States Dollars (“US$”))
(Audited)
NOTE 12 – RELATED PARTY TRANSACTIONS
The following table provides details of the total revenue earned and expenses incurred from all related party transactions:
For the year ended
December 31,
December 31,
2025
2024
Entities in which certain directors of a subsidiary have substantial financial interests
Sales of goods
$ 68,104
$ 112,556
Purchases
(9,503 )
(297,736 )
Rental of factory
(4,206 )
(1,969 )
The balances related to the above transactions with related parties are as disclosed in the Consolidated Balance Sheets which are interest-free, unsecured and subject to normal credit terms.
The related party being companies in which former directors have substantial financial interests.
NOTE 13 – CONCENTRATION OF RISKS
a) Major customers
There are no major customers who accounted for 10% or more of the Company’s revenue for the financial year ended December 31, 2025 and December 2024.
b) Major suppliers
For year ended December 31, 2025 and 2024, the suppliers who accounted for 10% or more of the Company’s cost of sales and their balances at year ended are presented as follows:
2025
2024
2025
2024
2025
2024
Purchase
Percentage of purchases
Accounts payable trade
Vendor A
$ 1,508,422
$ 1,635,124
23.83 %
19.89 %
$ -
$ 512,811
Vendor B
$ 950,001
$ 1,321,889
15.01 %
16.08 %
$ -
$ 168,302
Vendor C
$ -
$ 1,138,814
-
13.85 %
$ -
$ 160,521
$ 2,458,423
$ 4,095,827
38.84 %
49.82 %
$ -
$ 841,634
NOTE 14 – STOCKHOLDERS’ EQUITY
As at December 31, 2025 and 2024, the Company issued and outstanding, common stock of 2,417,314 and 1,796,766 shares respectively.
In August 2024, 300,000 shares of common stock were issued to professional parties or service providers in lieu of cash for services rendered.
Reverse Stock Split
On March 19, 2025, the Company held a Special Meeting of Shareholders which, among other items, approved of an amendment to the Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company’s outstanding shares of common stock, with a ratio ranging from one-for-five (1:5) to one-for-ten (1:10), with the exact ratio to ratio to be set at the discretion of the Board of Directors.
On April 1, 2025, the Company filed its Articles of Amendment with the Wyoming Secretary of State to effect a one for ten (1 for 10) reverse stock split of its issued and outstanding common stock. Immediately prior to the reverse stock split, the Company had 17,967,663 shares of common stock issued and outstanding and immediately after the reverse stock split, the Company had 1,796,597 shares of common stock issued and outstanding. No fractional shares were issued in connection with the reverse stock split. Instead, shareholders who would otherwise be entitled to receive a fractional share received a cash payment in lieu thereof based on the daily Volume Weighted Average Price (VWAP) of our common stock, calculated for ten (10) trading days immediately preceding the effective date of the Reverse Stock Split, multiplied by the fractional share.
The Revised Reverse Stock Split was approved and authorized by a majority of the Company’s stockholder on March 19, 2025. Thereafter, on that same date, the Board of Directors set the reverse stock split ratio at 1 for 10. The Reverse Stock Split was approved by the Board at a ratio of one-for-ten (1:10), an amendment was filed with the Wyoming Secretary of State on April 1, 2025, and became market effective on April 7, 2025.
F-27
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED DECEMBER 31, 2025 AND 2024
(Currency expressed in United States Dollars (“US$”))
(Audited)
Shelf Filing
On November 7, 2025, the Company filed a registration statement on Form S-3 with the U.S. Securities and Exchange Commission (“SEC”) to register up to $100 million of securities that may be offered from time to time. The Company concurrently entered into an Equity Distribution Agreement (the “Agreement”) with Maxim Group LLC (the “Agent”), pursuant to which the Company may offer and sell, from time to time, shares of its common stock, no par value (the “Common Stock”), having an aggregate offering price of up to $20,000,000 through the Agent, acting as the Company’s exclusive sales agent (the “ATM Program”).
Sales, if any, will be made in transactions deemed to be “at-the-market” offerings as defined in Rule 415 under the Securities Act of 1933, as amended, which may be made directly on The Nasdaq Capital Market or otherwise at prevailing market prices, at prices related to prevailing market prices, or at negotiated prices, as permitted by the Agreement. The Company is not obligated to sell any shares under the ATM Program, and the Agent is not required to purchase any shares. The Form S-3 became effective on November 27, 2025, and 53,478 shares have been sold for proceeds of $267,311 as of the date of filing of this Form 10-K.
In November 2025, the Company issued 175,000 shares of common stock to ARC Group Internation Ltd (‘ARC”) as consideration for ARC’s commitment under the purchase agreement to purchase, from time to time at the Company discretion, up to $500,000,000 of the Company’s common stock, no par value per share, over a 36-month period.
In November 2025, the Company issued 392,329 shares of common stock to Fidelion Diagnostics Pte. Ltd (“Fidelion”) as consideration for the Company’s subscription of Fidelion shares. This form part of the condition under the Share Subscription and Shareholders’ Agreement “SSSA” entered into with Fidelion and TongShu Biotechnology (Hong Kong) Co., Limited (‘TongShu”)
NOTE 15 – SEGMENT INFORMATION
The Company determines its reportable segments based on its internal organization structure and internal management reporting used to assess and allocate resources. This information are regularly reviewed by the Company’s Chief Executive Officer who is identified as the Chief Operating Decision Maker (“CODM”). The Company consists of three operating units, BioNexus Gene Lab Corp., MRNA Scientific Sdn. Bhd. and Chemrex Corporation Sdn. Bhd. which are determined as three reportable segments, as described below. These reportable segments offer different products and services, and are managed separately because they require different technology and marketing strategies. The following describes the operations in each of the Company’s reportable segments:
·
Trading of industrial chemicals
-
Includes trading of industrial chemicals
·
Provision for genomic screening services
-
includes in commercializing proprietary blood-based diagnostic test for early disease detection
·
Investment holding
-
Investment holding
The CODM evaluates the performance of each reportable segment based on operating income and key segment-specific metrics. There are no inter-segment revenue transactions between reportable segments. Except for investment holding activities and the revenue to the overseas customers as disclosed in Note 9, the Company’s revenue and principal operations are substantially confined within Malaysia.
Pursuant to ASU 2023-07, “Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures”, the financial information concerning the Company’s reportable segments is shown as below:
F-28
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED DECEMBER 31, 2025 AND 2024
(Currency expressed in United States Dollars (“US$”))
(Audited)
Provision for
genomic
Trading of
screening
industrial
Investment
services
chemicals
holding
Total
Year ended December 31, 2024
REVENUE
$ 16,069
$ 9,494,577
$ -
$ 9,510,646
COST OF REVENUE
(7,316 )
(8,213,809 )
-
(8,221,125 )
GROSS PROFIT
8,753
1,280,768
-
1,289,521
OTHER INCOME
122,951
1,949,522
-
2,072,473
OPERATING EXPENSES
Sales and marketing
(125,299 )
(1,861,456 )
(43,929 )
(2,030,684 )
Research and development
(47,511 )
-
-
(47,511 )
General and administrative
(194,038 )
(679,321 )
(959,609 )
(1,832,968 )
Share-base compensation
-
-
(141,000
)
(141,000
)
Provision for expected credit losses
-
(883,533 )
-
(883,533 )
TOTAL OPERATING EXPENSES
(366,848 )
(3,424,310 )
(1,144,538 )
(4,935,696 )
LOSS FROM OPERATIONS
(235,144 )
(194,020 )
(1,144,538 )
(1,573,702 )
FINANCE COSTS
(11,795 )
(9,072 )
(279 )
(21,146 )
LOSS BEFORE TAXES
(246,939 )
(203,092 )
(1,144,817 )
(1,594,848 )
Tax expense:
Deferred tax
-
12,305
-
12,305
Income tax
-
(15,799 )
-
(15,799 )
Tax expense
-
(3,494 )
-
(3,494 )
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS
$ (246,939 )
$ (206,586 )
$ (1,144,817 )
$ (1,598,342 )
F-29
Provision for genomic screening services
Trading of industrial chemicals
Investment holding
Total
Year ended December 31, 2025
REVENUE
$ 19,089
$ 7,405,822
$ -
$ 7,424,911
COST OF REVENUE
(9,335 )
(6,330,359 )
-
(6,339,694 )
GROSS PROFIT
9,754
1,075,463
-
1,085,217
OTHER INCOME
Dividend income
-
22,112
-
22,112
Interest income
73,274
10,614
-
83,888
Fair value gain on investments in equity securities
-
-
-
-
Gain on disposal of investments in equity securities
-
27,201
-
27,201
Reversal of expected credit losses
-
144,767
-
144,767
Gain from forex exchange
94,664
-
-
94,664
Others
10,514
48,971
-
59,485
TOTAL OTHER INCOME
178,452
253,665
-
432,117
OPERATING EXPENSES
Sales and marketing
(135,714 )
(1,548,420 )
(52,197 )
(1,736,331 )
Research and development
(50,670 )
-
-
(50,670 )
General and administrative
(211,467 )
(461,943 )
(862,042 )
(1,535,452 )
Share-base compensation
-
-
(794,770
)
(794,770
)
Fair value loss on investments in equity securities
-
(93,965 )
-
(93,965 )
Provision for expected credit losses
-
(271,211 )
-
(271,211 )
TOTAL OPERATING EXPENSES
(397,851 )
(2,375,539 )
(1,709,009 )
(4,482,399 )
LOSS FROM OPERATIONS
(209,645 )
(1,046,411 )
(1,709,009 )
(2,965,065 )
FINANCE COSTS
(12,709 )
(6,645 )
(188 )
(19,542 )
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS
$ (222,354 )
$ (1,053,056 )
$ (1,709,197 )
$ (2,984,607 )
Provision for
genomic
Trading of
screening
industrial
Investment
services
chemicals
holding
Total
Year ended December 31, 2024
Segment assets
$ 2,652,754
$ 6,788,302
$ 992,792
$ 10,433,848
Included in the measure of segment assets are:
Addition to non-current assets other than financial instruments and deferred tax assets
150,881
221,844
-
372,725
Provision for genomic screening services
Trading of industrial chemicals
Investment holding
Total
As of December 31, 2025
Segment assets
$ 2,281,947
$ 4,577,690
$ 2,393,147
$ 9,252,784
Included in the measure of segment assets are:
Addition to non-current assets other than financial instruments and deferred tax assets
1,382
35,589
-
36,971
The Company had no inter-segment sales for the years presented.
F-30
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED DECEMBER 31, 2025 AND 2024
(Currency expressed in United States Dollars (“US$”))
(Audited)
NOTE 16 – SIGNIFICANT EVENTS
On February 11, 2025, the Company filed with the Wyoming Secretary of State Articles of Amendment to its Articles of Incorporation (a true and correct copy of which is attached hereto as Exhibit 3.6) (“Amendment”). The Amendment authorized the creation of one (1) share of the Series Z Convertible Preferred Stock. On February 10, 2025, the Company’s Board of Directors approved the creation of the Series Z Preferred Stock and the filing of the Amendment with the Wyoming Secretary of State. On that same date, the Board of Directors approved the issuance of the Series Z Preferred Stock to Muhammad Azrul bin Abdul Hamid, a member of the Board of Directors and the Audit Committee.
The purpose of the Series Z Preferred Stock was to increase the likelihood of procuring the votes necessary to effectuate the Reverse Stock Split Proposal had a majority of the common stockholders voted in favor of the Reverse Stock Split Proposal in the Special Shareholders’ Meeting. The Series Z Preferred Stock proportionately “mirrored” the votes placed by the common stockholders of the Company at the Special Shareholders’ Meeting.
On March 5, 2025, the Company issued a press release announcing that its Board of Directors had formally approved a new treasury strategy focused exclusively on Ethereum (ETH) as a strategic treasury asset. This decision positioned the Company as a leader among Nasdaq-listed companies in prioritizing Ethereum for treasury management.
In connection with this announcement, the Company released an Ethereum Strategy Whitepaper, which provided detailed insight into the rationale for adopting Ethereum as a treasury asset. The whitepaper is publicly available on the Company’s website at www.bionexusgenelab.com/ethstrategy.
On March 7, 2025, the Company issued a press release announcing a strategic partnership with ML Tech to optimize its Ethereum-based growth strategies. ML Tech, an AI-driven wealth management platform for digital assets regulated by the National Futures Association (NFA) and headquartered in Miami, Florida, will provide institutional-grade trading strategies to BGLC.
On March 19, 2025, the Company held a Special Meeting of Shareholders. Two proposals were voted on by the Shareholders and the results are as follows:
Proposal 1 (APPROVED) : Approval of an amendment to the Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company’s outstanding shares of common stock, with a ratio ranging from one-for-five (1:5) to one-for-ten (1:10), with the exact ratio to be set at the discretion of the Board of Directors.
Proposal 2 (APPROVED): Approval of an adjournment of the Meeting, if necessary, to solicit additional proxies if there were insufficient votes in favor of Proposal 1.
On April 1, 2025, the Company’s Articles of Amendment regarding the reverse stock split was filed with the Wyoming Secretary of State. At 12:01 a.m. Eastern Time on April 7, 2025, the Company effected a reverse stock split and the Company’s common stock will began trading on a split-adjusted basis on The Nasdaq Capital Market under the existing ticker symbol “BGLC” on that same day, with the new CUSIP number for the Company 090628306.
No fractional shares were issued in connection with the reverse stock split. Instead, shareholders who would otherwise be entitled to receive a fractional share received a cash payment in lieu thereof based on the daily Volume Weighted Average Price (VWAP) of our common stock, calculated for the ten (10) trading days immediately preceding the effective date of the Reverse Stock Split, multiplied by the fractional share.
On November 12, 2025, the Company entered into a Share Subscription and Shareholders’ Agreement (the “SSSA”) by and among Fidelion, the Company, Tongshu Biotechnology (Hong Kong) Co., Limited (“Tongshu”), Mr. Su-Leng Tan Lee, Molecule Bio LLC and Rainy Morning Technology (Hong Kong) Limited.
Pursuant to the SSSA, the Company agreed to subscribe for newly issued ordinary shares of Fidelion such that the Company will hold at least 15.0% of Fidelion’s enlarged share capital at completion, in exchange for the Company issuing to Fidelion restricted shares representing 19.9% of the Company’s outstanding common stock (pre-issuance). Completion of the SSSA is subject to specified conditions precedent, including execution of a Southeast Asia intellectual property license between the Company and Fidelion and customary corporate and third-party consents.
On November 28, 2025, the Company entered into a Licensing Agreement with Fidelion. In consideration for the license, the Company agreed to pay Fidelion a total license fee of $2,000,000 in 24 equal monthly instalments and committed to purchase at least $500,000 in value of VitaGuard™ reagents and system component during the first 24 months following the effective date.
On November 28, 2025, the Company entered into an Equity Purchase Agreement (the “Purchase Agreement”) with ARC Group International Ltd. (“ARC”), the parent of ARC Group Securities, a FINRA registered broker/dealer. Under the terms of the Purchase Agreement, ARC has committed to purchase, from time to time at the Company’s discretion, up to $500,000,000 of the Company’s common stock, no par value per share (“Common Stock”), over a 36-month period (the “Facility”).
Under the Facility, the Company, in its sole discretion and subject to the terms and conditions of the Purchase Agreement, may direct ARC to purchase registered shares of Common Stock at a purchase price equal to a specified discount to the prevailing volume-weighted average price during an agreed pricing period, the discount being between 3.0% and 3.5%. ARC may not purchase shares under the Facility that would result in its beneficial ownership exceeding 9.99% of the Company’s then-outstanding Common Stock and is prohibited from short selling or hedging transactions involving the Company’s securities.
As consideration for ARC’s commitment under the Facility, the Company issued to ARC 175,000 shares of Common Stock (the “Commitment Shares”) on November 26, 2025.
On November 20, 2025, our Board of Directors has adopted the 2025 Equity Incentive Plan (the “Incentive Plan”), and later approved by our shareholders at our annual shareholders’ meeting in December 2025. The Plan allocated approximately 403,000 shares of common stock for issuance, subject to an annual share increase.
On December 19, 2025, the Company received notices of resignation from 4 (four) officers and directors of Chemrex. These individuals did not serve as executive officers of the Company.As at the filing date, the Company continues to assess any potential courses of action available to the Company or its subsidiaries. No conclusions have been reached, and any such assessments remain subject to further review.
F-31
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED DECEMBER 31, 2025 AND 2024
(Currency expressed in United States Dollars (“US$”))
(Audited)
NOTE 17 – SUBSEQUENT EVENTS
In accordance with ASC Topic 855, “Subsequent Events”, which establishes general standards of accounting for and disclosure of events that occur after the balance sheet date but before financial statements are issued, the Company has evaluated all events or transactions that occurred after December 31, 2025 up through April 14, 2026 of these consolidated financial statements.
During the period, the Company did not have any material recognizable subsequent events. During the year, there was no subsequent event that required recognition or disclosure, except for those previously disclosed.
F-32